Catherine Arnst A lot of patients’ hopes were dashed today with the news that Biogen Idec’s (NASDAQ: BIIB) closely watched drug dexpramipexole for amyotrophic lateral sclerosis (ALS) fai…
In a blow to both a high-flying biotech and the relatively few patients with Lou Gehrig’s disease, a Phase III clinical trial being run by Biogen Idec showed that its dexpramipexole for treating…
WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) ta…
The European Medicines Agency said it has launched a review of Merck & Co Inc's cholesterol drug Tredaptive after the medicine failed a U.S. trial assessing its effectiveness and safety. Although…
